APOE4 is a variant of the APOE gene, which provides instructions for making a protein that packages and transports cholesterol and other fats through the bloodstream. Everyone inherits two copies of the APOE gene (one from each parent), and those copies can be any combination of three variants: e2, e3, or e4. The e4 version is the one that raises concern because it is the single strongest genetic risk factor for Alzheimer’s disease and is also linked to higher rates of heart disease.
The Three APOE Variants
The APOE gene comes in three forms, and which two copies you carry shapes how your body handles cholesterol and how your brain clears waste proteins over a lifetime.
- APOE e3 is the most common variant worldwide. It is considered the baseline because it does not appear to raise or lower Alzheimer’s risk on its own.
- APOE e2 is the least common variant and is actually protective, reducing the risk of Alzheimer’s compared to e3.
- APOE e4 is moderately common. It increases the risk of Alzheimer’s and is associated with more severe disease when it does develop.
Because you carry two copies, your genotype might be e3/e3 (the most typical combination), e3/e4 (one risk copy), e4/e4 (two risk copies), or any other pairing. The number of e4 copies you carry matters: one copy raises your risk meaningfully, while two copies raise it substantially. People who carry two copies of APOE4 have been estimated to have roughly a 60% chance of developing Alzheimer’s dementia by age 85.
What the APOE Protein Does
The protein produced by the APOE gene combines with fats to form molecules called lipoproteins, which act as delivery vehicles for cholesterol. These vehicles shuttle cholesterol to cells that need it and help remove excess cholesterol from the bloodstream. In the brain, the APOE protein plays an additional role: it helps clear a waste protein called amyloid-beta, the substance that clumps into the plaques found in Alzheimer’s disease.
All three variants of APOE perform these jobs, but they don’t perform them equally well. The e4 version handles both cholesterol transport and brain cleanup differently, and those differences create problems over decades.
How APOE4 Raises Alzheimer’s Risk
The brain constantly produces amyloid-beta as a normal byproduct of cell activity. In a healthy brain, this waste is cleared efficiently through a barrier between the brain and bloodstream called the blood-brain barrier. The APOE protein helps shuttle amyloid-beta across this barrier and out of the brain.
When the APOE4 version of the protein binds to amyloid-beta, it redirects the waste to a slower removal pathway. Instead of using the brain’s fast-clearance receptor, the APOE4-amyloid complex gets routed to a receptor that processes material at a substantially slower rate. The result is a bottleneck: amyloid-beta builds up faster than it can be removed. Over years, this imbalance allows sticky plaques to accumulate between brain cells.
APOE4 also promotes a condition called cerebral amyloid angiopathy, where amyloid deposits build up in the walls of blood vessels in the brain, further compromising blood flow and waste removal. On top of that, research shows a dose-dependent increase in blood-brain barrier leakiness among APOE4 carriers. People with one copy show measurably more barrier permeability than non-carriers, and people with two copies show even more. A leakier barrier allows substances that normally stay in the bloodstream to seep into brain tissue, which can accelerate damage. This effect has been observed not only in Alzheimer’s patients but also in people without a dementia diagnosis.
APOE4 and Heart Disease
Alzheimer’s risk gets the most attention, but APOE4 also carries cardiovascular consequences. Carrying at least one copy of the e4 variant is consistently associated with a 26% to 42% higher risk of coronary heart disease compared to people with only e3 copies.
The mechanism ties back to how the protein handles cholesterol. The APOE4 protein binds more aggressively to LDL receptors on liver cells. This sounds like it would be helpful, but the strong binding actually causes the liver to pull its LDL receptors off the surface, a process called downregulation. With fewer receptors available, less LDL (“bad”) cholesterol gets removed from the blood. The result is higher circulating LDL levels. APOE4 also delays the processing of other fat-carrying particles, converting them into smaller, more harmful remnants that promote plaque buildup in artery walls.
Who Carries APOE4
APOE4 frequency varies significantly across populations and geography. The highest rates are found among Indigenous populations of sub-Saharan Africa, Scandinavia, Malaysia, and Australia, while the lowest rates appear in Japan, China, and Mediterranean populations. In the general U.S. population, roughly one in five people of European descent carries at least one copy.
Interestingly, carrying APOE4 does not confer the same degree of Alzheimer’s risk in every population. Some groups with high e4 frequencies do not show correspondingly high rates of Alzheimer’s, which suggests that other genetic factors, diet, and environment modify the gene’s impact. This is an active area of investigation, but it underscores that APOE4 is a risk factor, not a verdict.
Lifestyle Factors That Modify Risk
For people who carry one or two copies of APOE4, lifestyle choices appear to meaningfully shift the odds. Physical activity is one of the most studied interventions. A systematic review of the available research found that nearly all studies confirmed exercise as a protective factor against cognitive decline specifically in APOE4 carriers, with some evidence that more intense and more frequent activity provides greater benefit.
Diet also plays a role. The way APOE4 handles cholesterol means carriers tend to be more sensitive to dietary saturated fat than people with other genotypes. Diets lower in saturated fat and higher in vegetables, fish, and olive oil (patterns resembling the Mediterranean diet) may help blunt the cardiovascular and neurological effects of the variant. The combination of regular exercise and a heart-healthy diet addresses both the cholesterol transport problems and the brain-clearance issues tied to APOE4.
Genetic Testing for APOE4
APOE testing is available through both clinical genetic tests and consumer DNA kits. The test itself is straightforward: a saliva or blood sample reveals which two APOE variants you carry. What is less straightforward is deciding whether the information is useful to you.
A positive result (carrying one or two e4 copies) does not mean you will develop Alzheimer’s. Many carriers live into old age without cognitive decline, and many Alzheimer’s patients carry no e4 copies at all. APOE4 shifts probability, not certainty. For some people, knowing their status motivates concrete lifestyle changes. For others, it causes anxiety without providing a clear medical action plan, since no approved treatment can neutralize the APOE4 protein’s effects yet.
Gene therapy trials are underway that aim to introduce the protective e2 variant directly into the central nervous system of people who are APOE4 homozygotes, essentially trying to shift the balance of protein isoforms in the brain. These trials are still in early stages, focused on establishing safety and optimal dosing, but they represent the most direct attempt to address the root cause of APOE4-related risk rather than managing its downstream effects.